Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (tvfr-hypona): design and implementation of an open-label randomised trial

HIGHLIGHTS

• who: Annabelle M. Warren from the The University of Melbourne Victoria, Australia have published the Article: Tolvaptan versus fluid restriction in acutely hospitalised patients with moderate-profound hyponatraemia (TVFR-HypoNa): design and implementation of an open-label randomised trial, in the Journal: (JOURNAL) of 16/04/2021
• what: The authors seek to inform future international guidelines with high-quality data regarding the utility and safety of tolvaptan compared to standard therapy fluid restriction in patients with moderate-severe hyponatraemia in hospital. The trial is designed to determine superiority. The treating medical team will retain the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.